Eli Lilly's stock on pace for record close as Crohn's disease trial hits the markMarket Watch • 05/21/24
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have TodayThe Motley Fool • 05/21/24
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failurePRNewsWire • 05/21/24
Totus Medicines Announces Strategic Multi-Target Research Collaboration with LillyGlobeNewsWire • 05/16/24
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily InsulinPRNewsWire • 05/16/24
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound CopiesZacks Investment Research • 05/15/24
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance OfficerPRNewsWire • 05/15/24